DrugPatentWatch Database Preview
Cytogen Company Profile
» See Plans and Pricing
US Patents for Cytogen
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 9,447,431 | CureVac AG (Tubingen, DE) | 2032-02-15 | RX | search | |
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 9,364,567 | biOasis Technologies, Inc. (Richmond, CA) | 2033-03-13 | RX | search | |
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 9,211,315 | Halozyme, Inc. (San Diego, CA) | 2023-03-05 | RX | search | |
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 8,962,804 | City of Hope (Duarte, CA) | 2030-10-08 | RX | search | |
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 8,883,146 | AbbVie Inc. (North Chicago, IL) | 2027-11-30 | RX | search | |
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 8,722,019 | biOasis Technologies, Inc. (Vancouver, British Columbia, unknown) | 2031-08-05 | RX | search | |
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 8,420,081 | AbbVie, Inc. (North Chicago, IL) | 2027-11-30 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
